Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 V617F JAK2 G935R |
Therapy | Ruxolitinib |
Indication/Tumor Type | hematologic cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 G935R | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575). | 22271575 |
PubMed Id | Reference Title | Details |
---|---|---|
(22271575) | Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. | Full reference... |